Metabolic syndrome as a risk factor for diabetes

References

• Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care28, 2289–2304 (2005).
   PubMed Web of Science ®Google Scholar
• Yalow RS, Berson SA. Immunoassay of endogenous plasma insulin in man. J. Clin. Invest.39, 1157–1175 (1960).
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am. J. Physiol.237, E214–E223 (1979).
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Ferrannini E, Koivisto V. New concepts in the pathogenesis and treatment of noninsulin-dependent diabetes mellitus. Am. J. Med.74(1A), 52–81 (1983).
   PubMedGoogle Scholar
• Hollenbeck C, Reaven GM. Variations in insulin-stimulated glucose uptake in healthy individuals with normal glucose tolerance. J. Clin. Endocrinol. Metab.64, 1169–1173 (1987).
   PubMed Web of Science ®Google Scholar
• Reaven GM. Role of insulin resistance in human disease. Diabetes37, 1595–1607 (1988).
   PubMed Web of Science ®Google Scholar
• WHO. Definition, diagnosis, and classification of diabetes mellitus and its complications. Report of a WHO consultation. Part I: diagnosis and classification of diabetes mellitus. WHO, Geneva, Switzerland, WHO/NCO/NCS/99.2 (1999).
   Google Scholar
• Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet. Med.16, 442–443 (1999).
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA285, 2486–2497 (2001).
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation112, 2735–2752 (2005).
   PubMed Web of Science ®Google Scholar
• Einhorn D, Reaven GM, Cobin RH et al. ACE position statement on the insulin resistance syndrome. Endocr. Pract.9(3), 240–252 (2003).
   Google Scholar
• Alberti KG, Zimmet P, Shaw J. The metabolic syndrome – a new worldwide definition. Lancet366, 1059–1062 (2005).
   PubMed Web of Science ®Google Scholar
• Alberti KGMM, Eckel RH, Grundy SM et al. Harmonizing the metabolic syndrome. A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation120, 1640–1645 (2009).
   PubMed Web of Science ®Google Scholar
• Lorenzo C, Okoloise M, Williams K, Stern M, Haffner SM. The metabolic syndrome as predictor of Type 2 diabetes. The San Antonio Heart Study. Diabetes Care26, 3153–3159 (2003).
   PubMed Web of Science ®Google Scholar
• Lorenzo C, Williams K, Hunt KJ, Haffner SM. The National Cholesterol Education Program–Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care30, 8–13 (2007).
   PubMed Web of Science ®Google Scholar
• Wilson PWF, D’Agostino RB, Parise H, Sullivan L, Meigs J. Metabolic syndrome as a precursor of cardiovascular disease and Type 2 diabetes mellitus. Circulation112, 3066–3072 (2005).
   PubMed Web of Science ®Google Scholar
• Ford EA, Chaoyang L, Sattar N. Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care31, 1898–1904 (2008).
   PubMed Web of Science ®Google Scholar
• Sattar N, McConnachie A, Shaper AG et al. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet371, 1927–1935 (2008).
   PubMed Web of Science ®Google Scholar
• Wilson PWF, Meigs J, Sullivan L, Fox CS, Nathan DM, D’Agostino RB. Prediction of incident diabetes mellitus in middle-aged adults. The Framingham Offspring Study. Arch. Intern. Med.167, 1068–1074 (2007).
   PubMed Web of Science ®Google Scholar
• Kahn SE, Prigeon RL, McCulloch DK et al. Quantification of the relationship between insulin sensitivity and β-cell function in human subjects: evidence for a hyperbolic function. Diabetes42, 1663–1672 (1993).
   PubMed Web of Science ®Google Scholar
• Utzschneider KM, Prigeon RL, Carr DB et al. Impact of differences in fasting glucose and glucose tolerance on the hyperbolic relationship between insulin sensitivity and insulin responses. Diabetes Care29, 356–362 (2006).
   PubMedGoogle Scholar
• Gillies CL, Abrams KR, Lambert PC et al. Pharmacological and lifestyle interventions to prevent or delay Type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. Br. Med. J.334, 299–308 (2007).
   PubMed Web of Science ®Google Scholar
• Bray GA, K Jablonski KA, Fujimoto WY et al.; the Diabetes Prevention Program research group. Relation of central adiposity and body mass index to the development of diabetes in the Diabetes Prevention Program. Am. J. Clin. Nutr.87(5), 1212–1218 (2008).
   PubMed Web of Science ®Google Scholar
• Lindström J, Ilanne-Parikka P, Peltonen M et al.; the Finnish Diabetes Prevention study group. Sustained reduction in the incidence of Type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention study. Lancet368, 1673–1679 (2006).
   PubMed Web of Science ®Google Scholar
• Lilly M, Godwin M. Treating prediabetes with metformin. Systematic review and meta-analysis. Can. Fam. Physician55, 363–369 (2009).
   PubMedGoogle Scholar
• Ratzmann ML, Rjasanowski I, Bruns W, Ratzmann KP. Effects of clofibrate therapy on glucose tolerance, insulin secretion and serum lipids in subjects with hyperlipoproteinemia and impaired glucose tolerance. A follow-up study over a five-year period. Exp. Clin. Endocrinol.82(2), 216–221 (1983).
   Google Scholar
• Tenenbaum A, Motro, M, Fisman EZ et al. Peroxisome proliferators-activated Receptor ligand bezafibrate for prevention of Type 2 diabetes mellitus in patients with coronary artery disease. Circulation109, 2197–2202 (2004).
   PubMed Web of Science ®Google Scholar
• Canner PL, Furberg CD, McGovern ME. Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). Am. J. Cardiol.97, 477–479 (2006).
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Zhu D, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Relationship between glycemic status and progression of carotid intima-media thickness during treatment with combined statin and extended-release niacin in ARBITER 2. Vasc. Health Risk Manag.3, 159–164 (2007).
   PubMedGoogle Scholar
• Sasaki J, Iwashita M, Kono S. Statins: beneficial or adverse for glucose metabolism. J. Atheroscler. Thromb.13, 123–129 (2006).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FAH et al.; the JUPITER study group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med.359, 2195–2207 (2008).
   PubMed Web of Science ®Google Scholar
• Elliot WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet369, 201–207 (2007).
   PubMed Web of Science ®Google Scholar